Digital technologies for cognitive assessment to accelerate drug development in Alzheimer's disease.
For many neurological and psychiatric diseases, novel therapeutics have been elusive for decades. By focusing on attention interference in Alzheimer's disease (AD), we provide a future vision on how emerging mobile, computer, and device-based cognitive tools are converting classically noisy, subjective, data-poor clinical endpoints associated with neuropsychiatric disease assessment into a richer, scalable, and objective set of measurements. Incorporation of such endpoints into clinical drug trials holds promise for more quickly and efficiently developing new medicines.
Neuroscience & Pain Research Unit, BioTherapeutics, Worldwide Research and Development, Pfizer Inc., Cambridge, Massachusetts, USA.
C
C
Leurent
Neuroscience & Pain Research Unit, BioTherapeutics, Worldwide Research and Development, Pfizer Inc., Cambridge, Massachusetts, USA.
M D
MD
Ehlers
D000544:Alzheimer Disease / Q000175:diagnosis* / Q000188:drug therapy / Q000523:psychology; D003072:Cognition Disorders / Q000175:diagnosis* / Q000188:drug therapy / Q000523:psychology; D055808:Drug Discovery / Q000379:methods* / Q000639:trends; D006801:Humans; D000068997:Smartphone / Q000706:statistics & numerical data* / Q000639:trends; D017216:Telemedicine / Q000706:statistics & numerical data* / Q000639:trends